

ISPOR EUROPE 2024

Time to Rethink Your Global Launch

11/19/2024

outwit complexity™



Increasing complexity drives a need for us to generate evidence earlier, develop more complex analyses, adopt new digital tools and collect richer data

Growing Complexities



Fragmented set of analytical requirements for JCA process



Pharma innovation has created increasingly **complex products**



Heterogenous payer decision criteria across global markets

Needs / Gaps

- Conduct earlier evidence generation and payer engagement activities
- > Develop and utilise complex health-economic models with local inputs and assumptions
- Integrate digital tools to improve internal coordination and efficiency
- Effectively collect and manage data and key business learnings to continue to improve decision making

This growing complexity drives a need for pharma to plan and execute earlier and increase efficiency



We see the confluence of access, digital, and evidence as being key to helping pharma companies navigate this growing complexity

Access

Thinking about access and value in innovative ways beyond the traditional price-volume paradigm



Digital

New tools incorporating novel visualisation platforms, AI and machine learning

Evidence

Generate high-quality ex-RCT data, customised for multiple stakeholders



As a result, we have developed several innovative tools that help bring together access, digital and evidence in meaningful ways

01 Integrated Evidence Plan


IEP

Early, aligned evidence planning to overcome gaps in our value story

02 Price Policy Tool

DPT

Platform that streamlines the global price policy process





03 Global Access Database

GAP

Optimise ex-US strategy with an interactive, single source of data

04 Submission Dashboard

DASH

Integrate launch workstreams and align across functional groups







© 2024 Guidehouse



Integrated evidence planning at an early stage is critical in ensuring that functions are aligned and that key stakeholder needs are addressed at the time of launch

Integrated Evidence Planning (IEP)





Objective

Ensure evidence addresses stakeholder needs and key value messages to support regulatory approval, access, product development, and more

How

Define stakeholders and develop key value messages, map evidence needs to key value messages and identify key gaps

Why

Ensure all functions are aligned on evidence activities, and that value messages are ready for all stakeholders when needed



Digitisation of global pricing streamlines a relatively inefficient and recursive standard global pricing policy process

Digital Pricing Tool (DPT)



Objective

Increase efficiency during global price policy planning and implementation through digitisation

How

Providing users with an intuitive digital interface to submit business cases and for all teams to view global feedback


Why

This tool supports seamless policy decisionmaking and allows for iteration based on best practices, leading to faster approval time and better resource allocation



Our Geographical Access Prioritisation tool draws on our broad in-house expertise across markets to facilitate ex-US product launch or expansion planning

Geographical Access Prioritisation (GAP)



Detailed Market Overviews



Comparison of Regulatory and Access Outlook Between Markets



Indication
Prioritisation
within Markets

Objective

A digital tool that synthesises key data to enable comparison of regulatory and P&MA potential across global markets in an accessible dashboard


How

An interactive, single source of comprehensive market access data helps create a snapshot of current global opportunities

Why

Allows for faster, deeper, insight-driven decisionmaking around market and indication prioritisation during global launches The submission dashboard tool increases coordination efficiency during the global launch submission process

Submission Dashboard Tool (DASH)



Objective

Tackling inefficiencies in cross-functional coordination during the global launch submission process

How

Articulates key milestones to local teams, acts as a repository for submission materials, and allows for performance tracking

Why

Increasing efficiency and coordination could reduce risk of launch delays and sub-optimal pricing outcomes



In conclusion, overcoming increasing complexity requires us to rethink our global launch planning by combining access, digital and evidence in new, meaningful ways



Earlier planning and execution

Examples of challenges solved:


- · Heterogenous payer decision criteria
- Increasing product complexity



Market-specific evidence and models

Example of challenges solved:

- Heterogenous payer decision criteria
- · Fragmented requirements for JCA





Use of digital tools to coordinate planning

Examples of challenges solved:

- Fragmented requirements for JCA
- Heterogenous payer decision criteria



Better data collection to improve decision-making

Examples of challenges solved:

- Fragmented requirements for JCA
- Heterogenous payer decision criteria

Accelerate and expand market access potential to maximize asset value

© 2024 Guidehouse



Our expert panel spans a wide range of experience across the healthcare ecosystem to ensure that solutions are tailored to your individual strategic needs



Karla Anderson
Partner

Presenting at | | | | | | | | | |



Andy Longosz
Director





Gaelle Marinoni
Director



Shahzad Ali Associate Director



Jacob Graham Partner



Chance Scott
Partner



Youbean Oak Director



Fred Sieling
Director



John Wang Director



Tiffany Yu Associate Director



Digital Analyses and Visualisations



Complex Strategic Decision-Making Support



Broad and Deep Therapeutic Area Experience



Traditional and "Non-Traditional"

Markets Experience



Healthcare Ecosystem Knowledge



Integrated Med Affairs, HEOR and Market Access Analysis